CHAMPIONS ONCOLOGY INC

CSBRNASDAQ

🏆 #4296 by market capEarnings Dec 14US Equity

$402.02▲ $28.26 (+7.03%)

Simulated price

🔔

Track CSBR

Get earnings, price moves & breaking news on Telegram

Track

24h▲ 7.0%

7d—

14d—

30d—

ytd—

1y—

🏦Market Cap

$68M

Small Cap

📈Revenue Growth (YoY)

+4.4%

Slowing

📊Gross Margin

49.3%

Healthy

💵FCF Margin

-10.1%

Thin

⚖️P/S Ratio

1.1x

Cheap

Otter Score

Good

No chart data available for CSBR.

Trading Snapshot

Day Range: $398.66 – $404.20
52-Week Range: $4.59 – $8.31
Volume: $4.41B
Avg Volume: $4.98B
Shares Outstanding: 13.9M
Next Earnings: Nov 3, 2026

Fundamentals Snapshot

Annual Revenue: $61M
Last Q Revenue: $15M
P/E Ratio: -62.4
P/S Ratio: 1.1x
EPS (TTM): $-0.08
Dividend Yield: 0.00%
Dilution (1yr): −3.9%

Why Investors Own CSBR

✓High-growth profile — revenue up +25.5% YoY with expanding US Equity exposure.
✓Healthy economics — 78% gross margin and 24% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

CHAMPIONS ONCOLOGY INC

CSBR

Financial Trends

Revenue

$59M▲ +4.4% YoY

Gross Margin

48.0%▼ −4.3% YoY

Operating Income

−$1M▼ −123.5% YoY

Free Cash Flow

−$5M▼ −172.0% YoY

Shares Outstanding

13.9M▼ −3.9% YoY

Net Cash

−$7M▼ −$10M YoY

StockOtter · stockotter.space

About CHAMPIONS ONCOLOGY INC

Champions Oncology, Inc. is dedicated to developing and commercializing cutting-edge technological products and services designed to personalize cancer treatment and streamline the development of oncology drugs across the United States. At the heart of its offerings is the Tumorgraft Technology Platform, an innovative approach that facilitates individualized cancer care by implanting human tumors into immune-deficient mice. Utilizing this proprietary platform, the company not only delivers personalized cancer solutions directly but also provides Translational Oncology Solutions, supporting pharmaceutical and biotechnology companies through their drug development lifecycle. Additionally, Champions Oncology offers Lumin Bioinformatics, a comprehensive software platform and data tool filled with insights from research services and clinical studies, accessible through annual subscriptions. The company distributes its offerings through various channels, including online platforms, word-of-mouth referrals, and a dedicated sales team, reaching both patients and healthcare professionals. Established in 1985, Champions Oncology, Inc. is based in Hackensack, New Jersey, and was formerly known as Champions Biotechnology, Inc. until its name change in April 2011.

🦦